Education
About Us
Working with TipRanks
Follow Us
Quanterix (QTRX)
:QTRX
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.25Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -12.91%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
Quanterix demonstrated resilience in consumables and strategic advancements, such as new product launches and significant merger synergies, but faced challenges with declining total revenue, increased expenses, and macroeconomic pressures leading to a more conservative revenue outlook.Company Guidance
During Quanterix Corporation's first quarter 2025 earnings call, several key financial metrics and strategic updates were discussed. The company reported a revenue of $30.3 million, representing a 5% decline year-over-year, but highlighted a record quarter for consumables, which grew by 6% to $18.1 million. The adjusted gross margin was approximately 50%, and adjusted cash usage improved by over 50%, amounting to $9 million. The company anticipates achieving positive cash flow by 2026, supported by a balance sheet exceeding $100 million. An amended merger with Akoya Biosciences was also announced, reducing the equity value by 67% to $66 million, while increasing Quanterix's shareholder ownership to 84% of the combined company. Additionally, the firm outlined strategic initiatives, including the upcoming launch of the Simoa ONE platform, which promises up to 10x the sensitivity of existing systems and aims to expand into immunology and oncology markets. The company has set a revenue guidance range for 2025 between $120 million and $130 million, factoring in challenges such as reduced NIH funding and pharma spending.Record Consumables Revenue
Quanterix recorded its highest consumables quarter, with consumables revenue reaching $18.1 million, up 6% from the previous year.
Strategic Initiatives and Product Launches
The company launched four new immunology assays, building on 20 new assays introduced last year, and plans to release the next-gen platform Simoa ONE by year-end.
Akoya Biosciences Merger Synergies
The merger with Akoya is expected to increase Quanterix's shareholder ownership from 70% to 84% and contribute significantly to top-line and gross profit dollars.
Operational Efficiency and Cost Savings
Quanterix announced a $30 million core operating cost reduction, scaling to $55 million annualized savings by 2026, contributing to a path towards positive cash flow.
---
QTRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
QTRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $5.73 | $4.64 | -19.02% |
Mar 17, 2025 | $7.28 | $7.15 | -1.79% |
Nov 12, 2024 | $15.17 | $12.40 | -18.26% |
Aug 08, 2024 | $12.82 | $10.92 | -14.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Quanterix (QTRX) report earnings?
Quanterix (QTRX) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Quanterix (QTRX) earnings time?
Quanterix (QTRX) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QTRX EPS forecast?
QTRX EPS forecast for the fiscal quarter 2025 (Q2) is -0.4.
---